EICHOR
● Recruiting
A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty
Condition: Central Precocious Puberty · Sponsor: LG Chem
About this study
A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children with Central Precocious Puberty
This description comes directly from the study's public registry record.
Talk to the study team
Clinical Study Lead · 02-6987-4151 · lgclinical@lgchem.com
Always discuss trial participation with your own doctor first.
Locations (1)
| Kangdong Sacred Heart Hospital | Seoul, South Korea | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07710430